相关实验视频

Updated: Jan 7, 2026

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

多发性骨髓瘤中的CAR T细胞:到达起跑线的比赛

Abdul-Hamid Bazarbachi^1,2, Divaya Bhutani³, Michael Sang Hughes³

¹Division of Hematology/Oncology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USA. bazarbachi@gmail.com.

Bone marrow transplantation

|December 27, 2025

概括

包括idecabtagene vicleucel和ciltacabtagene autoleucel在内的CAR T细胞疗法在多发性髓瘤中表现有前途. 现实数据揭示了特定患者群体的访问,安全和结果方面的挑战.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

多发性骨髓瘤的治疗正在随着CAR T细胞疗法的发展而发展.
伊德卡巴丁维克卢塞尔 (Idecabtagene vicleucel) 和西尔塔卡巴丁自动卢塞尔 (Ciltacabtagene autoleucel) 已在严重预先治疗的患者中显示出有效性.
像KarMMa-3和CARTITUDE-4这样的临床试验支持早期使用这些疗法.

研究的目的:

综合更新的随机和现实世界的证据,用于多发性骨髓瘤中CAR T细胞疗法.
检查具有挑战性的种群,新出现的毒性和影响结果的操作因素.
引导CAR T细胞疗法的最佳整合到临床实践中.

主要方法:

更新的随机对照试验数据的审查.
从新兴患者队伍中分析现实世界的证据.
检查安全概况,包括感染相关的死亡率.
评估影响患者结果的访问和交付限制.

主要成果:

在早期的治疗线路中,CAR T细胞疗法在标准疗法上表现出优越性.
现实数据强调了输注前的消耗和高风险患者的异质结果.
安全标志包括感染驱动的非复发性死亡率.
运营因素显著影响患者的益处和治疗的交付.

结论:

卡尔T细胞疗法正在改变多发性骨髓瘤的治疗方法,其适用范围正在扩大.
现实世界的有效性是由患者特定的因素和后勤挑战所塑造的.
需要在目标,构造和制造方面进行进一步的创新,以优化CAR T细胞治疗的交付并扩大其应用.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...